|Bid||0.00 x 1100|
|Ask||0.00 x 900|
|Day's Range||330.62 - 336.63|
|52 Week Range||226.02 - 337.96|
|Beta (3Y Monthly)||1.11|
|PE Ratio (TTM)||83.82|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||1.36 (0.41%)|
|1y Target Est||341.27|
Chemed's (CHE) VITAS shows higher adoption via an expanded average daily census. Also, the Roto-Rooter's business grows on the back of strong core plumbing and drain cleaning service segments.
The launch of this system is in sync with NuVasive's (NUVA) endeavor to deliver end-to-end solutions that offer predictable clinical and economic outcomes in spine surgery.
Boston Scientific (BSX) is currently pinning hopes on a stronger performance in China, backed by the recent approval of SYNERGY in the country.
4D surgical techniques for insertion of UroLift System implants and a single-centre study showing significant cost savings with the use of the UroLift System treatment compared with traditional surgery. Teleflex Incorporated (TFX) today thanked its United Kingdom-based Physician Advocates for their Poster Presentations highlighting the UroLift® System, as well as real world proof of its cost effectiveness, at this year’s BAUS meeting which finished on June 26th. The first Presentation, by Dr. Mark Rochester*, Consultant Urologist from Norfolk and Norwich University Hospital, shared promising, early results of the UroLift System treatment of BPH patients with acute urinary retention.
ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.
Integra LifeSciences (IART) expects its partnership with Tissue Analytics to be perfectly strategic as the latter's software solutions automatically derive high quality data from clinical pictures.
The identification of a group of peptides and proteins is a remarkable step toward Phibro's (PAHC) development of a solution for ASF.
WAYNE, Pa., July 09, 2019 -- Teleflex Incorporated (NYSE: TFX) today announced the publication of positive results from a multi-center study reaffirming the safety and.
The sale of oncology bead products by Boston Scientific (BSX) is expected to be among the last steps undertaken by the company to obtain Federal Trade Commission's approval for BTG buyout.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Teleflex Incorporated and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
Teleflex (TFX) issued a statement saying consumers who own the tampered product should immediately discontinue use and return all affected products.